IL2 and neoplasm: The rapid expansion protocol, first described by the Rosenberg group, uses anti-CD3 monoclonal antibody (OKT3), high dose interleukin-2 (IL-2) and irradiated allogenic feeder cells to generate T cell for adoptive therapy from tumour infiltrating lymphocytes.15 To study whether SR could support expansion of T cells activated using soluble anti-CD3 monoclonal antibody and feeder cells, polyclonal T cells were activated according to the rapid expansion protocol and cultured in XVIVO15, OpTmizer or CTS AIM-V supplemented with either HS or SR.